4.8 Article

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Immunology

Identification of novel Plasmodium vivax proteins associated with protection against clinical malaria

Ramin Mazhari et al.

Summary: As progress is made towards eliminating malaria, the challenge of Plasmodium vivax becomes more apparent. In regions where both P. vivax and Plasmodium falciparum are co-endemic, the proportion of P. vivax cases has increased as transmission declines. The lack of advanced vaccines for P. vivax and limited potential candidates highlight the need for novel tools for accelerated elimination. In this study, researchers aimed to identify promising P. vivax proteins for a subunit vaccination approach by screening protein constructs and confirming previous results, as well as discovering four novel candidates with predicted protective efficacy.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Article Medicine, Research & Experimental

Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine

Carolyn M. Nielsen et al.

Summary: Modifications to vaccine delivery, specifically delayed fractional (DFx) dosing, can significantly increase the durability of serum antibodies. This study demonstrates that DFx dosing improves the magnitude and longevity of circulating B cells and IgG1 antibodies. The underlying mechanisms include improved FcRn binding and a shift from short-lived plasma cells to long-lived plasma cells.

JCI INSIGHT (2023)

Article Multidisciplinary Sciences

Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine

Myriam Arevalo-Herrera et al.

Summary: In this randomized, double-blind, controlled vaccine clinical trial, the authors evaluate the protective efficacy of a Plasmodium vivax circumsporozoite (CS) protein vaccine in both naive and semi-immune individuals and explore the antibody and IFN-gamma response to the vaccine.

NATURE COMMUNICATIONS (2022)

Article Multidisciplinary Sciences

Prevalence and risk of Plasmodium vivax infection among Duffy-negative individuals: a systematic review and meta-analysis

Polrat Wilairatana et al.

Summary: This study used a meta-analysis approach to investigate the prevalence and risk of Plasmodium vivax infection among Duffy-negative individuals. The results showed that P. vivax infection could occur among Duffy-negative individuals, but the prevalence was relatively low.

SCIENTIFIC REPORTS (2022)

Article Biochemistry & Molecular Biology

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Rebecca P. Payne et al.

Summary: The study demonstrates that the first dose of the BNT162b2 mRNA vaccine can induce protection against the B.1.1.7 variant within weeks, and extending the interval between doses can result in higher levels of neutralizing antibody response. Prior infection with the virus can accelerate the immune response.
Article Medicine, Research & Experimental

Controlled human malaria infection with a clone of Plasmodium vivax with high- quality genome assembly

Angela M. Minassian et al.

Summary: This study reported safe infection of two healthy UK adults with a clone of P. vivax from Thailand through mosquito-bite CHMI, resulting in a high-quality genome assembly and identification of 1145 VIR genes.

JCI INSIGHT (2021)

Article Medicine, General & Internal

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Amy Flaxman et al.

Summary: The study shows that an extended interval before the second dose of the AstraZeneca vaccine leads to increased antibody titres, while a third dose significantly boosts antibody levels and enhances T-cell responses.

LANCET (2021)

Article Medicine, Research & Experimental

Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination

Angela M. Minassian et al.

Summary: The study conducted a clinical trial in the UK to evaluate the safety, immunogenicity, and efficacy of the RH5.1 recombinant protein vaccine, finding that a delayed and fractional third dose regimen significantly improved antibody response longevity and led to a significant reduction in parasite growth rate following primary and secondary blood-stage P. falciparum infections in vaccinees. The data provide a new framework for designing and delivering next-generation malaria vaccines.
Review Parasitology

Plasmodium vivax in the Era of the Shrinking P. falciparum Map

Ric N. Price et al.

TRENDS IN PARASITOLOGY (2020)

Review Microbiology

Malaria Vaccines: Recent Advances and New Horizons

Simon J. Draper et al.

CELL HOST & MICROBE (2018)

Article Biochemistry & Molecular Biology

Cytotoxic CD8+ T cells recognize and kill Plasmodium vivax-infected reticulocytes

Caroline Junqueira et al.

NATURE MEDICINE (2018)

Article Medicine, Research & Experimental

Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies

Ruth O. Payne et al.

JCI INSIGHT (2017)

Article Immunology

Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy Volunteers

James S. McCarthy et al.

JOURNAL OF INFECTIOUS DISEASES (2013)

Article Multidisciplinary Sciences

Fya/Fyb antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria

Christopher L. King et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)

Article Multidisciplinary Sciences

Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection

Christopher L. King et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)